From GlobeNewswire: 2025-05-08 02:19:00

BioPorto A/S announced Q1 2025 financial results, with revenue of DKK 7.7 million and an EBITDA loss of DKK 28.1 million. NGAL sales in the U.S. grew by 20%, but declined in the rest of the world. The company maintained its 2025 revenue guidance of DKK 45-60 million and an adjusted EBITDA loss of DKK 75-85 million.

Progress continues on strategic milestones for BioPorto A/S in Q1 2025, including preparations for the commercial launch of ProNephro AKI NGAL in the U.S. for pediatric use. NGAL Research Use Only (RUO) sales in the U.S. grew by 20%, exceeding expectations. Enrollment in the adult clinical study progressed faster than anticipated.

BioPorto A/S successfully completed a funding round on April 16, 2025, issuing 25,000,000 new shares and raising gross proceeds of DKK 33.5 million. The company’s CEO, Peter Mørch Eriksen, expressed satisfaction with the progress made in Q1 2025, highlighting continued growth in NGAL RUO sales in the U.S. and progress towards 2025 milestones.



Read more at GlobeNewswire:: Continued progress on key strategic milestones in Q1 2025.